drugset

drugset / Trial / NCT04343859

A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors

NCT04343859 ↗

Phase 1 Unknown 96 enrolled Tianjin Chasesun Pharmaceutical Co., LTD

NaSingle-groupOpen-labelTreatment

Summary

Phase I study of IMMH-010 in patients with advanced malignant solid tumors

Timeline

Start: 2020-05-14
Primary completion: 2024-12
Completion: 2024-12

Publications

Jiang J, Zou X, Liu Y, Liu X, Dong K, Yao X, Feng Z, Chen X, Sheng L, Li Y. Simultaneous Determination of a Novel PD-L1 Inhibitor, IMMH-010, and Its Active Metabolite, YPD-29B, in Rat Biological Matrices by Polarity-Switching Liquid Chromatography-Tandem Mass Spectrometry: Application to ADME Studies. Front Pharmacol. 2021 Jun 21;12:677120. doi: 10.3389/fphar.2021.677120. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMMH-010	Small molecule	360 mg	—

Indications